Advertisements

Magnosolv

Quick links to important sections

Magnosolv

Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Magnosolv

Quick Facts

Property Description
Active Ingredient Magnesium Carbonate, Magnesium Oxide
Form Granules for Oral Solution (Powder in Sachets)
Pharmacological Class Mineral Supplement, Electrolyte
Common Use Magnesium Replenishment
Origin Derived (Processed Mineral Salts)

What Type of Medicine is Magnosolv?

Magnosolv is a pharmaceutical preparation widely recognized as both a Mineral Supplement and an Electrolyte intended for systemic use. It is primarily utilized to deliver the essential Magnesium Cation to the body when stores are depleted. The Anatomical Therapeutic Chemical (ATC) classification system places magnesium salts under the A12CC group for mineral supplements.

This medicine is specifically designed as a Combination Product, leveraging the distinct properties of two salts, Magnesium Carbonate and Magnesium Oxide, to optimize the delivery of the active substance. This formulation distinguishes it from single-salt magnesium preparations.

Composition and Physical Form of Magnosolv

The Active Ingredients in Magnosolv are Magnesium Carbonate and Magnesium Oxide, both common compounds in pharmaceutical formulations intended to elevate serum magnesium levels. Magnesium is an Essential Mineral required for hundreds of bodily functions, including enzyme actions and cellular energy production. The product is supplied in the specialized Dosage Form of Granules for Oral Solution (Powder in Sachets), requiring reconstitution with water prior to Oral (Peroral) administration.

What is the General Purpose of Taking Magnosolv?

The general purpose of taking Magnosolv is to replenish or restore the body’s overall Magnesium Stores when a deficiency is identified. This action is clinically recognized as a mechanism to aid in supporting the numerous Physiological Actions where magnesium acts as a Cofactor, assisting with proper nerve signaling, muscle function, and the regulation of heartbeat rhythm. The core benefit is the maintenance of internal Electrolyte Balance and general physiological health by systematically compensating for the observed mineral shortfall.

Regulatory References

  1. Magnesium Carbonate
  2. Magnesium Oxide
Advertisements

What side effects are possible with Magnosolv?

Possible Side Effects and Safety Information

The safety profile for oral magnesium salts, such as the active ingredients in Magnosolv, is primarily characterized by effects on the Gastrointestinal System and the risk of systemic toxicity (Hypermagnesaemia), particularly in specific populations. This information is derived from official government regulatory documents.

Adverse Reaction Scope

The most commonly reported adverse reaction is Diarrhea, which is often dose-dependent and classified as Common in regulatory frequency frameworks. Other adverse effects listed under Gastrointestinal Disorders include nausea, vomiting, and abdominal cramping.

Systemic effects are generally associated with Hypermagnesaemia, which occurs when magnesium levels become too high. Serious adverse reactions documented in this context include effects on the Nervous System (e.g., drowsiness, confusion) and Cardiac/Vascular Disorders (e.g., severe hypotension, arrhythmias, or cardiac arrest), which are rare but clinically significant.

Safety-Related Restrictions and Considerations

The most critical safety constraint noted in official labeling is the risk associated with impaired kidney function. Since magnesium is eliminated by the kidneys, individuals with severe renal impairment are at a high risk for magnesium accumulation and toxicity. Therefore, severe renal impairment is explicitly listed as a contraindication for use. Additionally, administration is restricted in cases of known hypersensitivity or suspected bowel obstruction.

Advertisements

Overdose and Emergency Response

The regulatory documentation for Magnosolv addresses the potential for overdose leading to the state of Hypermagnesemia, which is magnesium toxicity. The onset of overdose may be indicated by initial manifestations such as hypotension (low blood pressure), skin flushing, muscle weakness, and the depression or loss of deep tendon reflexes. The disappearance of the patellar reflex is a specific clinical sign noted in official guidance.

Immediate medical attention must be sought right away if an overdose is suspected or if severe signs appear. The official profile lists respiratory paralysis, heart block, and ultimately cardiac arrest as potential life-threatening outcomes. Overdosage can be fatal, particularly when serum magnesium concentrations rise significantly.

In the event of severe hypermagnesemia, treatment involves the immediate discontinuation of the medication. A specific antidote, an injectable calcium salt (such as Intravenous Calcium Gluconate), must be administered to counteract the severe neuromuscular and cardiac effects. Artificial ventilation may be required. Management often includes symptomatic and supportive care, with dialysis being a documented measure for severe toxicity, especially in patients with impaired renal function. Regulatory warnings emphasize that patients with pre-existing kidney conditions are at greater risk of developing this toxic state.

Advertisements

Therapeutic Uses of Magnosolv

What Magnosolv Treats: Main Uses and Benefits

Magnosolv is commonly used in contexts involving systemic imbalance, providing supportive relief by addressing low magnesium stores, which is an essential requirement for normal nerve and muscle function. The medicine is applied across therapeutic domains where additional symptomatic support is needed in contexts involving systemic imbalance.

Key Therapeutic Domains

The product is relevant for easing symptoms related to physical discomfort, which may present as symptoms of increased neurological or muscular activity, such as nocturnal leg cramps, muscle spasms, or muscle twitching (fasciculations). It is also commonly used in clinical settings where supportive symptom management is appropriate, and may be part of symptomatic management for migraine headaches and other recurrent or episodic manifestations. Additionally, the product is applied in scenarios where short-term symptomatic assistance is needed for temporary digestive issues, including occasional constipation and symptoms related to mild acid indigestion or heartburn.


Quick Fact: Supportive Role for Muscle and Nerve Symptoms

Symptom Category Benefit Provided
Neuromuscular Hyperactivity Supports the patient in addressing symptoms related to muscle spasms and cramps.
Recurrent Discomfort Contributes to easing the overall symptom load related to heightened physiological activity (e.g., migraine).
Temporary GI Issues Supports the patient during difficult episodes by easing distress related to occasional constipation or mild hyperacidity.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Magnosolv?

This section outlines the official population eligibility and non-eligibility rules for Magnosolv (Magnesium Carbonate/Magnesium Oxide) as documented by governmental regulatory bodies. Use is generally allowed for the General Adult Population requiring magnesium replenishment.


Contraindications and Restrictions

Population / Condition Regulatory Status
Severely Impaired Renal Function Contraindicated (High risk of hypermagnesemia)
Known Hypersensitivity Contraindicated (Allergy to magnesium salts or excipients)
Existing Hypermagnesemia Contraindicated (Would worsen the condition)
Any Degree of Renal Impairment Restricted Use (Requires caution and monitoring)
Neuromuscular Disorders (e.g., Myasthenia Gravis) Restricted Use (Requires caution)
Pediatric Population Use Not Established or restricted below a documented age limit.

Older adults require caution, especially those with reduced kidney function, due to an increased risk of toxicity. For pregnancy and lactation, use is typically conditional and generally permitted only after clinical consultation.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for oral magnesium salts, such as those in Magnosolv, details interaction patterns related to absorption interference and additive systemic effects. This information is derived exclusively from governmental drug labels and monographs.

Administration-Timing Requirements

To prevent reduced absorption and maintain the effectiveness of certain co-administered treatments, the regulatory labeling mandates a strict time separation. Drugs susceptible to chelation or gastrointestinal pH alteration, specifically Tetracycline and Quinolone Antibiotics, Bisphosphonates, and Iron preparations, must be administered separated by a period of 2 to 4 hours from this medicine.

Exposure and Homeostasis Interactions

The risk of hypermagnesemia (elevated magnesium concentration) is a primary exposure concern and is heightened when co-administered with other magnesium-containing preparations (e.g., certain antacids or laxatives). Furthermore, regulatory documents identify several drug classes that can disrupt magnesium homeostasis by causing increased magnesium loss or reduced intestinal absorption, notably Loop and Thiazide Diuretics, Proton Pump Inhibitors (PPIs), and EGF-receptor antagonists. The profile also notes that high doses of Zinc or Calcium supplements can interfere with intestinal magnesium absorption.

Population and Pharmacodynamic Notes

Patients with severe renal impairment are officially noted to be at a significantly increased risk of magnesium accumulation and subsequent toxicity due to reduced kidney clearance. The profile further documents a pharmacodynamic risk of potentiation when co-administered with Neuromuscular Blocking Agents.

Advertisements

Mechanism of Action

The mechanism of action of Magnosolv centers on the multifaceted biological role of its active ingredient, magnesium. It is classified as an agent that influences signaling within pathways associated with altered physiological activity by acting on key regulatory systems.

Essential Cofactor and Stabilizer in Cellular Energy

Magnosolv primarily acts by restoring optimal magnesium homeostasis, which is required for cellular function. Magnesium is an essential cofactor that binds to and activates adenosine triphosphate ( ATP), enabling the proper transfer of energy. This mechanistic domain facilitates the integrity of ion pumps and ensures the necessary metabolic function required to maintain resting membrane potential and cell membrane potential integrity.

Modulation of Neuromuscular Excitability

The drug modulates activity within specific neural pathways by serving as a non-competitive calcium antagonist. Mg^2+ ions interfere with Ca^2+ signaling at the neuromuscular junction, dampening the influx of calcium required for excessive neurotransmitter release. This targeted pathway interference decreases the frequency or amplitude of signaling events; a mechanistic consequence is the alteration of nerve and muscle action potential characteristics.

Influence on Smooth Muscle Tone and Signal Transduction

Magnosolv engages molecular cascades within the vascular system, influencing the molecular steps governing smooth muscle contraction. By antagonizing Ca^2+ and inhibiting enzymes like myosin light-chain kinase ( MLCK), the drug facilitates vasodilation at the cellular level. This alters activity in molecular cascades associated with smooth muscle excitation in peripheral pathways, influencing systemic consequences arising from peripheral pathway modulation.

Advertisements

Dosage and Administration Information

Magnosolv is administered via the oral route, with the dosage form supplied as granules for oral solution (powder in sachets). Administration requires the powder to be dissolved completely in water before consumption, a preparation method typical for mineral supplements.

Labeled Administration Protocol

Administration Feature Instruction
Standard Adult Dose 1 to 2 sachets daily, equivalent to 365 mg to 730 mg elemental Magnesium.
Frequency Pattern Administered once or twice daily.
Course Duration The standard course for treating chronic deficiency is typically four weeks.
Pediatric Rules Specific dose ranges are provided for children aged 6 to 14 years, which may involve divided partial doses.

Administration follows specific procedural constraints: to prevent compromised absorption, a 3- to 4-hour interval must be observed between taking Magnosolv and certain other oral preparations, including those containing iron, tetracyclines, and sodium fluoride. The use of this medicine is restricted or contraindicated in individuals with severe renal impairment. The formulation is specified as suitable for patients with diabetes.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Magnosolv

The research base for the active components of Magnosolv (magnesium salts) has been primarily evaluated through clinical studies and formal evidence reviews, focusing on how the body's magnesium levels relate to certain health contexts. Studies examine how symptoms evolve in the observed populations, and research provides insight into short-term changes. Findings describe group patterns, not personal outcomes, and evidence highlights what is known and what is still uncertain.


Evidence for Confirmed Magnesium Deficiency

Research examined the use of magnesium salts for the correction of a confirmed lack of magnesium in the body, a condition known as Hypomagnesemia. Research for this context includes a variety of Clinical Trials and Observational Studies, which monitor the body's internal electrolyte balance. The collected data show patterns related to the restoration and normalization of the serum magnesium concentration (a key physiological measure). Research describes the relationship between magnesium supplementation and changes in deficiency-related symptoms. The main evidence for this use is well-established; however, research primarily focuses on the short-term correction of the low biomarker level, and long-term effects are not fully established regarding sustained outcomes for chronic, milder deficiency states.


Evidence for use in Migraine Prevention

Research has explored the role of magnesium salts in conditions characterized by fluctuating or episodic manifestations, specifically the prevention of migraine headaches. This research was evaluated in Randomized Controlled Trials (RCTs) and is summarized in Systematic Reviews. These studies focused on outcomes related to episodic or acute changes, such as measuring the frequency and intensity of attacks. Findings from trials indicate patterns related to monitored outcomes collected over defined time intervals, with the common follow-up duration being 12 weeks (3 months). Evidence quality varies across studies, and the findings were mixed due to inconsistency in the specific magnesium salt or dose used. Therefore, certainty in this area remains low.


What Remains Less Certain in the Research

Research highlights several areas where certainty remains low or further data are needed. For contexts like nocturnal leg cramps, where the available evidence is limited and heterogeneous (studies differ widely), findings were mixed. Furthermore, research examining whether the specific combination of magnesium salts in Magnosolv yields different outcome patterns compared to single-salt preparations is limited. Ultimately, research provides context but not individual predictions, and the long-term effects are not fully established across all contexts.

Key Studies & References

  1. Hypomagnesemia - Endocrine and Metabolic Disorders (Clinical Guideline for Magnesium Deficiency)
  2. Magnesium - StatPearls (Overview of Magnesium Use and Deficiency)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Magnosolv (FAQ)


Q: What are the official indications for Magnosolv in my country?

A: According to the official product information provided by regulatory documents, Magnosolv is indicated for addressing confirmed magnesium deficiency, a condition known as hypomagnesaemia. It is also indicated for the prevention of migraine attacks, according to the specific authorization granted in the region.


Q: Has Magnosolv been studied for use during pregnancy?

A: Studies on magnesium supplementation have been examined, and official documentation notes that the use of Magnosolv during pregnancy is typically conditional. Like many medicines, its use in this population is generally permitted only after clinical consultation is recommended.


Q: Can Magnosolv be taken during breastfeeding?

A: Official information regarding Magnosolv generally permits conditional use during lactation. Magnesium absorption by an infant via breast milk is considered low. However, clinical consultation is recommended.


Q: How quickly do the effects of Magnosolv usually start?

A: Regulatory sources that describe how the drug moves through the body indicate that oral magnesium is slowly and incompletely absorbed. Magnesium absorption in the blood typically occurs over several hours after administration, with peak concentration noted around 2 to 3 hours.


Q: Can Magnosolv be taken alongside vitamin D supplements?

A: Information from regulatory sources indicates that combining magnesium with certain types of Vitamin D analogs may increase the risk of developing hypermagnesemia, which means elevated magnesium blood levels. This may be a concern, particularly for populations with reduced kidney function.


Q: What does 'bioavailability' mean when referring to Magnosolv?

A: Bioavailability is a pharmacological term that refers to the rate and extent to which the active ingredient is absorbed from the product and becomes available in the body's circulation to produce an effect. Magnosolv is formulated specifically to facilitate the delivery of the magnesium cation.


Q: Why is Magnosolv sometimes described as being better absorbed than other forms of magnesium?

A: Magnosolv is a specific pharmaceutical combination of two different magnesium salts: Magnesium Carbonate and Magnesium Oxide. This deliberate combination is designed by the manufacturer to facilitate the delivery and absorption of the elemental magnesium compared to single-salt preparations.


Q: Does Magnosolv cause headaches or dizziness?

A: Headaches and dizziness are not typically listed among the common adverse effects in official safety profiles. However, these symptoms can be manifestations of high magnesium levels (hypermagnesemia), which is a documented, but rare, systemic adverse reaction associated with magnesium accumulation.


Q: Is Magnosolv the same thing as regular magnesium supplements?

A: Magnosolv is a combination product that is regulated as a specific pharmaceutical preparation and electrolyte intended for systemic use. This distinction sets it apart from general dietary supplements that may not be subject to the same strict regulatory standards for production and intended purpose.


Q: Why is Magnosolv described as a 'prophylactic' treatment?

A: The term prophylactic is used because the official indications for Magnosolv include the use of magnesium for the prevention of certain conditions. This means it is used to guard against a condition developing or recurring, rather than just treating an acute existing symptom.


Q: Can Magnosolv be taken with food, or does it have to be on an empty stomach?

A: Official administration instructions do not impose strict restrictions on taking it with food. However, when magnesium salts are used for certain effects, some regulatory guidance advises against taking it on a late-day or empty stomach, but this typically refers to its laxative properties.


Q: What is the longest period of time people typically use Magnosolv?

A: The standard duration for the official treatment of chronic magnesium deficiency is typically noted in regulatory documents as four weeks. Use that extends beyond this established period should be guided by a healthcare professional, based on the specific need and continuous monitoring.


Q: Are there any specific dietary restrictions when taking Magnosolv?

A: Official interaction sections do not list general food restrictions. However, co-administration with high doses of mineral supplements such as Calcium or Zinc can interfere with the amount of magnesium absorbed. Consult with a professional if you are following a highly specialized diet.


Q: What is the difference between Magnosolv and other magnesium salts like magnesium oxide?

A: Magnosolv is a unique formulation because it is a combination product that contains two distinct magnesium salts: Magnesium Carbonate and Magnesium Oxide. Many other supplements available contain only one type of magnesium salt.


Q: What happens if I miss taking Magnosolv for a day?

A: Regulatory guidance suggests that if a scheduled dose is missed, it can typically be taken as soon as it is remembered. However, if it is almost time for the next dose, the missed dose should be skipped entirely to prevent accidentally taking a double dose.


Q: Does Magnosolv cause tiredness or fatigue?

A: Tiredness and fatigue are not typically listed as common side effects. Regulatory documents do note that severe tiredness, drowsiness, or muscle weakness are documented symptoms that can occur if there is an overdose or accumulation of magnesium (hypermagnesemia).


Q: Can Magnosolv be taken at any time of day?

A: Magnosolv is officially administered once or twice daily, allowing for flexibility in timing. The intake is often flexible, but it should be separated by 3–4 hours from certain other medications, like iron preparations or some antibiotics, to prevent interactions.


Q: Does Magnosolv interfere with iron absorption?

A: Regulatory documents confirm that magnesium is known to interfere with the absorption of iron preparations in the digestive system. For this reason, official instructions mandate a separation of 3 to 4 hours between taking Magnosolv and any iron supplements.


Q: Can I use less water than recommended to dissolve the powder?

A: Official instructions for administration specify the amount of water required to ensure the powder dissolves properly. Using less water than the minimum recommended amount may compromise dissolution.


Q: What happens if I accidentally take more Magnosolv than advised?

A: Taking more than the advised amount significantly increases the risk of high magnesium levels in the body, known as hypermagnesemia. Official documents note that symptoms of overdose can include diarrhea, nausea, muscle weakness, and, in severe cases, central nervous system depression.

Advertisements

How should Magnosolv be stored and disposed of?

How to Store and Dispose of Magnosolv (Magnesium Aspartate)

The official guidelines for storing and disposing of Magnosolv (powder for oral solution) ensure product stability and safety.

Storage Conditions

Product State Maximum Temperature Storage Duration
Unreconstituted Powder Not above 25 C Shelf-life: 3 years
Reconstituted Solution Below 25 C (conditional) Use immediately; up to 24 hours if mixed with bottled water

All medicinal products, including Magnosolv, must be kept out of the sight and reach of children. The powder should remain in its original sachet until use.

Disposal

Any unused or expired Magnosolv, including waste material, must be disposed of in accordance with local requirements established by regional health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Magnosolv found in:

A-Z Index: